Sphera Funds Management Ltd. C4 Therapeutics, Inc. Transaction History

Sphera Funds Management Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$5.06 - $26.46 $1.74 Million - $9.08 Million	343,208 Added 94.67%	705,736 $5.32 Million
Q1 2022 May 16, 2022	SELL	$19.99 - $33.23 $718,460 - $1.19 Million	-35,941 Reduced 9.02%	362,528 $8.8 Million
Q4 2021 Feb 14, 2022	BUY	$29.39 - $46.86 $490,666 - $782,327	16,695 Added 4.37%	398,469 $12.8 Million
Q3 2021 Nov 15, 2021	SELL	$35.91 - $50.5 $4.91 Million - $6.91 Million	-136,837 Reduced 26.39%	381,774 $17.1 Million
Q2 2021 Aug 17, 2021	BUY	$30.39 - $42.18 $652,625 - $905,815	21,475 Added 4.32%	518,611 $19.6 Million
Q1 2021 May 17, 2021	BUY	$31.96 - $46.5 $1.7 Million - $2.48 Million	53,312 Added 12.01%	497,136 $18.4 Million
Q4 2020 Feb 16, 2021	BUY	$22.8 - $37.05 $10.1 Million - $16.4 Million	443,824 New	443,824 $14.6 Million

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $170M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.